DSpace Repository

Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029

Show simple item record

dc.contributor Universitat de Vic. Càtedra de la Sida i Malalties Relacionades
dc.contributor.author Surdo, M.
dc.contributor.author Alteri, C.
dc.contributor.author Puertas, M.C.
dc.contributor.author Saccomandi, P.
dc.contributor.author Parrotta, L.
dc.contributor.author Swenson, L.
dc.contributor.author Chapman, D.
dc.contributor.author Costa, G.
dc.contributor.author Artese, A.
dc.contributor.author Balestra, E.
dc.contributor.author Aquaro, S.
dc.contributor.author Alcaro, S.
dc.contributor.author Lewis, M.
dc.contributor.author Clotet, Bonaventura
dc.contributor.author Harrigan, R.
dc.contributor.author Valdez, H.
dc.contributor.author Svicher, V.
dc.contributor.author Perno, C.F.
dc.contributor.author Martinez Picado, Francisco Javier
dc.contributor.author Ceccherini-Silberstein, Francesca
dc.date.accessioned 2015-04-20T11:02:30Z
dc.date.available 2015-04-20T11:02:30Z
dc.date.created 2015
dc.date.issued 2015
dc.identifier.citation Surdo, M., Alteri, C., Puertas, M. C., Saccomandi, P., Parrotta, L., Swenson, L., et al. (2015). Effect of maraviroc on non-R5 tropic HIV-1: Refined analysis of subjects from the phase IIb study A4001029. Clinical Microbiology and Infection, 21(1), 103.e1-103.e6. ca_ES
dc.identifier.issn 1198-743X
dc.identifier.uri http://hdl.handle.net/10854/3997
dc.description.abstract We characterized maraviroc susceptibility of dual/mixed tropic viruses from subjects enrolled onto phase IIb study A4001029. Maraviroc baseline plasma samples from 13 multidrugexperienced subjects were sequenced and the HIV-1-env gene cloned into pNL4.3Δenv to obtain recombinant viruses. The V3 region was sequenced by the Sanger method and ultradeep sequencing. By analysing subjects having a weighted optimized background therapy susceptibility (wOBT) score of <1, 3/7 subjects were characterized by good in vivo and in vitro response to maraviroc therapy. Molecular docking simulations allowed us to rationalize the maraviroc susceptibility of dual/mixed tropic viruses. A subset of subjects with dual/mixed tropic viruses responded to maraviroc. Further investigations are warranted of CCR5 antagonists in subjects carrying dual/mixed tropic virus that explore the feasible use of maraviroc in subjects that is potentially larger than those infected with a pure R5 virus. ca_ES
dc.format application/pdf
dc.format.extent 6 p. ca_ES
dc.language.iso eng ca_ES
dc.publisher Wiley ca_ES
dc.rights Tots els drets reservats ca_ES
dc.rights (c) Wiley
dc.subject.other Sida -- Tractament ca_ES
dc.title Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029 ca_ES
dc.type info:eu-repo/semantics/article ca_ES
dc.identifier.doi https://doi.org/10.1016/j.cmi.2014.08.002
dc.rights.accessRights info:eu-repo/semantics/closedAccess ca_ES
dc.type.version info:eu-repo/publishedVersion ca_ES
dc.indexacio Indexat a SCOPUS ca_ES

Files in this item

Show simple item record

Search RIUVic

Advanced Search